News
RNA viruses are renowned for their elegant structure and finely tuned self‐assembly processes, which are critical both for viral life cycles and for potential applications in nanotechnology and ...
However, their use in RNA therapeutics has remained largely undeveloped due to the challenges of constructing supraparticles that are both structurally precise and biologically functional. A ... the ...
Visualizing RNA Assembly: From Cryo-Electron ... E.K.S., Zhang, M. et al. Non-averaged single-molecule tertiary structures reveal RNA self-folding through individual-particle cryo ...
They also demonstrate successful assembly in unconventional “buffer” substances including nickel. These developments, published in the journal Science Advances ("Counter ions influence the isothermal ...
Hosted on MSN2mon
Self-amplifying RNA synthesis market to reach $310.8m by 2030 - MSNThe global self-amplifying ribonucleic acid (RNA) synthesis market is projected to reach $310.8m by 2030 at a compound annual growth rate of 19.24%, according to Research and Markets.
Our cells need to be able to recognize potential invaders as a threat, the key function of the body's innate immune system. Sometimes this process fails, causing the body to react to its own cells ...
New genetic vaccines using self-replicative RNA. Self-replicative RNA vaccines are capable of protecting mice against influenza A, respiratory syncytial virus (RSV), and a tick-borne encephalitis ...
Replicate Bioscience has early evidence its self-replicating RNA technology works in humans. The Apple Tree Partners biotech showed all doses of its rabies vaccine triggered protective responses, ...
Immunomic Therapeutics Announces Presentation on Self-amplifying RNA vaccines using the UNITE® platform for Triple-negative Breast Cancer at SITC 39 th Annual Meeting 2024 November 06, 2024 09:00 ...
BOSTON, Jan. 14, 2025 /PRNewswire/ -- Keylicon Biosciences is pleased to announce its exclusive rights to a groundbreaking next-generation RNA technology developed at Boston University. This ...
Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results